SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
NEW YORK, Jan. 22, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased MannKind Corp. (Nasdaq:MNKD) securities between August 10, 2015 and January 5, 2016.
Click here to learn about the case: http://docs.wongesq.com/MNKD-Info-Request-Form-1078. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements and/or failed to disclose that: (1) contrary to Defendants’ assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza, the Company’s rapid-acting insulin; and (2) as a result, Defendants’ statements about MannKind’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in MannKind you have until March 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/MNKD-Info-Request-Form-1078.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
